TOPRA's One-Day Biotech Meeting
Understanding your biotech product? analytical and bio-analytical characterization.
Understanding Your Biotech Product-Analytical and Bio-analytical Characterization
Dates:
Wednesday
28th January 2009
Venue:
Radisson SAS
Portman Hotel
London, UK
Aims of the course
To ensure that delegates have the appropriate knowledge in the field of analytical and bioanalytical characterization to allow them to undertake their professional roles and specifically as follows:
• The techniques used to characterize biopharmaceutical medicinal products
• Regulatory requirements and expectations for characterisation data at different stages of the product development cycle
• Impact of process variables on product quality
• Requirements for comparability assessment following process changes
• Importance of characterisation techniques in a biosimilar product MAA.
Who should attend
The conference is designed for regulatory staff who are working with biotechnology-derived products, particularly those who may not have first hand manufacturing or process development experience, and those who are new to regulatory affairs. This conference would also be useful for anyone wishing to refresh his or her knowledge in the area.
Programme includes:
• Analytical characterisation concentrating on in vitro and biophysical techniques
• Bio-analytical techniques concentrating on bioassays and agency expectations for bioassays
• Impact of process variables on product quality
• Comparability assessment example following a major process change (a case study from Wyeth)
• Regulatory Agency perspective on comparability
• Biosimilars
Speakers include:
• Paul Chamberlain, Director, NDA Advisory Board, UK
• Brendan Fish, Director Bio-analytical Group, MedImmune, UK
• Brian Fitzpatrick, Associate Director of Analytical Development, Wyeth, Eire
• Stephen Fitzpatrick, Head of CMC RA, UCB Pharma Ltd, UK
• Kowid Ho, Biologicals/Biotechnology Unit, AFSSaPS, France
• Paul Jeffreys, Senior Manager RA, Eisai, UK
• Meg Leahey, Associate director, Wyeth Biotech, Eire
• Cecil Nick, Vice President, Parexel Consulting , UK
• Jane Robinson, NIBSC, UK
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Ponsegromab Significantly Improves Body Weight in Patients with Cancer Cachexia
September 17th 2024Results of a Phase II study of ponsegromab showed significant improvements in body weight, muscle function, and overall symptoms for patients with cancer cachexia, offering hope for a new targeted treatment.
Imfinzi Plus Imjudo Shows Significant Five-Year Survival Improvement in Unresectable Liver Cancer
September 16th 2024Data from the Phase III HIMALAYA trial found the combination of Imfinzi plus Imjudo reduced the risk of death by 24% compared to sorafenib in patients with unresectable hepatocellular carcinoma.
